Tarsus officer plans $340K stock sale in 2026

Tarsus Pharmaceuticals, Inc. (TARS) has a planned sale of common stock under Rule 144 by officer Elizabeth Yeu-Lin through Fidelity Brokerage Services LLC.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) has a planned sale of common stock under Rule 144 by officer Elizabeth Yeu-Lin through Fidelity Brokerage Services LLC. The notice covers 4,601 shares of common stock, tied to an aggregate value of $339,829.86, with Tarsus having 43,882,996 shares outstanding and an approximate sale date of September 1, 2026.

The securities relate to restricted stock that vested on June 16, 2023 (2,000 shares) and June 22, 2024 (2,601 shares), both characterized as compensation from the issuer.

Key Figures

Shares to be sold: 4,601 shares Aggregate market value: $339,829.86 Shares outstanding: 43,882,996 shares +2 more

5 metrics

Shares to be sold 4,601 shares Common stock covered by the Rule 144 notice

Aggregate market value $339,829.86 Value associated with the 4,601 shares of common stock

Shares outstanding 43,882,996 shares Common shares outstanding for Tarsus Pharmaceuticals, Inc.

Restricted stock vesting (June 16, 2023) 2,000 shares Compensation-related restricted stock vesting from the issuer

Restricted stock vesting (June 22, 2024) 2,601 shares Compensation-related restricted stock vesting from the issuer

Key Terms

Rule 144, restricted stock vesting, aggregate market value, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Common | 06/16/2023 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregate market value financial

"Common | Fidelity Brokerage Services LLC ... | 4601 | 339829.86"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

attorney-in-fact regulatory

"as attorney-in-fact for Elizabeth Yeu-Lin"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing indicate for TARS?

It indicates that an officer, Elizabeth Yeu-Lin, has filed a notice to sell 4,601 shares of Tarsus Pharmaceuticals, Inc. common stock under Rule 144 through Fidelity Brokerage Services LLC, with an approximate sale date of September 1, 2026.

How many Tarsus (TARS) shares are planned to be sold under this Rule 144 notice?

The notice covers 4,601 shares of Tarsus Pharmaceuticals, Inc. common stock, associated with an aggregate market value of $339,829.86, with the sale to be executed through Fidelity Brokerage Services LLC.

What restricted stock grants underpin the planned TARS share sale?

The planned sale is tied to restricted stock vesting awards of 2,000 shares that vested on June 16, 2023 and 2,601 shares that vested on June 22, 2024, both listed as compensation from Tarsus Pharmaceuticals, Inc.

How many Tarsus (TARS) shares are outstanding in this notice?

The notice reports that Tarsus Pharmaceuticals, Inc. has 43,882,996 shares outstanding of common stock. This figure provides context for the relative size of the planned 4,601-share sale under Rule 144.

Who is executing the planned TARS share sale and in what capacity?

The sale is to be executed through Fidelity Brokerage Services LLC. The Form 144 is signed by Wade Moss as a duly authorized representative of Fidelity, acting as attorney-in-fact for officer Elizabeth Yeu-Lin.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 02:23 PM Accepted by SEC EDGAR 09/01/2026 - 02:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001842190
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tarsus Pharmaceuticals, Inc.
SEC File Number	001-39614
Address of Issuer	15440 LAGUNA CANYON ROAD IRVINE CALIFORNIA 92618
Phone	(949) 409-9820
Name of Person for Whose Account the Securities are To Be Sold	Lin Elizabeth Yeu
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4601	339829.86	43882996	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/16/2023	Restricted Stock Vesting	Issuer			2000	06/16/2023	Compensation
Common	06/22/2024	Restricted Stock Vesting	Issuer			2601	06/22/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Elizabeth Yeu-Lin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)